Nicox S.A. announced that it will be focusing the future development of NCX 4251 on dry eye disease. This decision follows the encouraging post hoc results from the Mississippi Phase 2b clinical trial and a subsequent positive meeting with the U.S. Food and Drug Administration (FDA). Further pharmaceutical development activities will need to be completed to support the next steps in the clinical development of NCX 4251.

The clinical trials are not currently financed, per the recently announced cash runway of Fourth Quarter 2023.